Across TCGA pan-cancer cohorts, CHML mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHML data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CHML mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHML expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, LUAD, and GBM are the cancer types where CHML mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	1.000	0.386	.002	28	view →
LUAD	OS	Quartile	II,III,IV	0.410	1.000	.024	6	view →
GBM	DFS	Quartile	All	0.824	0.591	.040	2	view →
PDAC	OS	Median	II,III,IV	0.407	0.629	.022	2	view →
LSCC	DFS	Median	All	1.000	0.905	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CHML tumor-vs-normal RNA expression · all CHML data types